Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Pharma Alarmed By Regional Variations In ICH's Draft Biowaiver Guideline

Executive Summary

European drug companies have expressed concern over region-specific requirements variations permitted in an ICH guideline that proposes a harmonized approach to granting waivers for in vivo bioequivalence studies.

You may also be interested in...



M9 Biowaivers Guidance Nearly Harmonised During ICH Meeting

Experts came close to harmonizing draft ICH M9 guidance on biowaivers, which allow in-vitro in lieu of in-vivo bioequivalence testing under certain circumstances. Final guidance is expected soon, Drug Information Association annual meeting told.

Digital Data Deluge Can Affect Oversight Of Patient Safety In Trials

The digitalization of clinical trials is generating more patient safety data than companies can process. A senior EMA official says sponsors should carefully select what is needed to maintain appropriate subject oversight by “getting the science right.”

Companies Urged Not To View EU Privacy Law As A Barrier To Conducting Decentralized Trials

A senior regulator from the European Medicines Agency says that while the EU General Data Protection Regulation can be intellectually challenging, the law is needed, and it should not deter companies from conducting decentralized clinical trials because of concerns they might have over the use digital tools to capture and process patient and trial data.

Topics

UsernamePublicRestriction

Register

PS124839

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel